Drug Database
Back to search

Netherlands· NL-38ed15a5d05f

Rydapt 25 mg, zachte capsule

A midostaurin product containing midostaurine, registered in Netherlands by Novartis Europharm Limited. The same ATC class is registered in 12 of our 19 countries.

ATC L01EX10

Checked against CBG-MEB (Netherlands) on

Informational only — not a medical device.

SOURCE REGISTER · NLCBG-MEB (Netherlands)normalisedRydapt 25 mg, zachte capsuleATCL01EX10REGISTER NO.NL-38ed15a5d05fPACKS LISTED1CHECKEDSeptember 29, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about midostaurineAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Midostaurin is registered in 12 of 19 countries.

Countries holding a registration under ATC L01EX10 (midostaurin), each read from that country’s own register.

  • This record: Netherlands, from CBG-MEB (Netherlands)
  • 8 of them publish a price we can compare per daily dose
Search midostaurin products by name

Midostaurin · ATC L01EX10

12 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

CBG-MEB (Netherlands)
Active substance
MIDOSTAURINE
Manufacturer
Novartis Europharm Limited
Country
Netherlands (NL)
ATC code
L01EX10
ATC class
Midostaurin
Defined daily dose
0.1 g, O
Reimbursed
Not published by this register
Source register
CBG-MEB (Netherlands)
Last checked
September 29, 2026

Packs & prices · 1

  • cbg_meb_id
    EU/1/17/1218

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

582 interactions on record for midostaurin.

Graded by severity as the source publishes them — 132 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check midostaurin against other medicinesHow interaction checks work

Midostaurin · interactions on record

582 records

  • 132 severe
  • 445 moderate
  • 5 minor

Most severe, free to view

  • PapaverineA03AD01severe
  • CisaprideA03FA02severe
  • DolasetronA04AA04severe
  • LonafarnibA16AX20severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Midostaurin in 14 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All midostaurin products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Iceland · Rydapt
  • Liechtenstein · Rydapt
  • Norway · Rydapt

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/2a1a21a9-05bc-4b81-8cda-b99d99f3475c
GET /v1/drugs/2a1a21a9-05bc-4b81-8cda-b99d99f3475c?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Capsule, zacht",
  "route": "Oraal gebruik",
  "soort": null,
  "source": "cbg_meb",
  "smpc_url": "https://www.ema.europa.eu/en/documents/product-information/rydapt-epar-product-information_nl.pdf",
  "strength": null,
  "atc_label": "Midostaurin",
  "detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/cp119772",
  "excipients": [
    "ETHANOL",
    "GELATINE (E 441)",
    "GLYCEROL 85 PER CENT (E 422)",
    "HYPROMELLOSE 2910 (3 - 15 mPa.s) (E 464)",
    "IJZEROXIDE GEEL (E 172)",
    "IJZEROXIDE ROOD  (E 172)",
    "KARMIJN (E120)",
    "MACROGOL 400",
    "MACROGOLGLYCEROLHYDROXYSTEARAAT",
    "MAÏSOLIE, MONO-DI-TRIGLYCERIDE ESTERS",
    "PROPYLEENGLYCOL (E 1520)",
    "RODE INKT",
    "TITAANDIOXIDE (E 171)",
    "TOCOFEROL, DL-ALFA (E 307)",
    "WATER, GEZUIVERD"
  ],
  "substances": [
    "MIDOSTAURINE"
  ],
  "leaflet_url": null,
  "authorised_at": "2017/09/19",
  "procedure_number": "EMEA/H/C/004095",
  "dispensing_status": "Uitsluitend recept",
  "registration_number": "EU/1/17/1218",
  "additional_monitoring": "N"
}
API referenceMCP serverPlans

See everything about midostaurin.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console